Sign up to save your podcasts
Or
Share 5 Things You Need to Know in Cervical Cancer: New and Emerging Agents
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
5 Things You Need to Know in Cervical Cancer: New and Emerging Agents
CME credits: 0.25
Valid until: 29-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/5-things-you-need-to-know-in-cervical-cancer-new-and-emerging-agents/14102/
The global burden of cervical cancer is immense, especially for patients who have failed first-line therapy. Second-line interventions have historically had low response rates of short duration. But the landscape is changing with new and emerging agents in late-stage clinical trials, including antibody- drug conjugates, immunotherapy regimens, and tumor-infiltrating lymphocyte therapies. Join Drs. Robert Coleman and Kathleen Moore as they discuss and distill the “need to know” findings about these more effective therapies—therapies destined to improve outcomes for patients whose cervical cancer has failed first-line therapy.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 29-09-2023
Claim your CME credit at https://reachmd.com/programs/cme/5-things-you-need-to-know-in-cervical-cancer-new-and-emerging-agents/14102/
The global burden of cervical cancer is immense, especially for patients who have failed first-line therapy. Second-line interventions have historically had low response rates of short duration. But the landscape is changing with new and emerging agents in late-stage clinical trials, including antibody- drug conjugates, immunotherapy regimens, and tumor-infiltrating lymphocyte therapies. Join Drs. Robert Coleman and Kathleen Moore as they discuss and distill the “need to know” findings about these more effective therapies—therapies destined to improve outcomes for patients whose cervical cancer has failed first-line therapy.
=